Lung cancer is responsible for more fatalities each year than breast cancer, colon cancer and prostate cancer combined. 

The LiquidLung™ liquid biopsy program, designed for targeted screening, confirmatory diagnosis and histologic typing and subtyping of lung cancer, is positioned to rule more patients with an elevated risk of developing lung cancer into evidence-based imaging pathways earlier, eliminate unnecessary invasive biopsies for patients with suspicious pulmonary nodules discovered incidentally and/or through routine screening, and to accelerate the time to the most precise histology-specific treatment. 

The patented LiquidLung™ program has been extensively validated, with our team of internal and external partners successfully completing 43 R&D studies, including 17 independent cross-cohort validations, across 7 independent patient cohorts and 4,692 case-control clinical specimens, with strong reproducibility and best-in-class diagnostic sensitivity and specificity achieved in all studies.